Clinical stage biopharmaceutical company: OHR Pharmaceutical (OHRP)

OHR Pharmaceutical, Inc. (NASDAQ:OHRP) is headquartered in New York, New York, USA, with 3 full-time employees. It is a clinical-stage pharmaceutical company that develops new treatments for eye diseases.

OHR Pharmaceutical

OHR Pharmaceutical (OHRP):

OHR Pharmaceutical has completed two clinical trials using a 0.2% squalamine lactate ophthalmic solution for the treatment of wet age-related macular degeneration.

In addition, OHR Pharmaceuticals also has a slow-release micro-manufactured microparticle ophthalmic drug delivery platform technology.

The company intends to merge with NeuBase Therapeutics, Inc., focusing on advancing NeuBase’s peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapeutic methods to solve serious and currently incurable diseases caused by genetic mutations.

Notify of
Inline Feedbacks
View all Intels

British biotech company: COMPASS Pathways plc (CMPS) (2012)

US prescription drug discount platform: GoodRx Holdings (GDRX) (2015)